Lack of Benefit of Fluvoxamine for COVID-19

被引:5
作者
Bhimraj, Adarsh [1 ,3 ]
Gallagher, Jason C. [2 ]
机构
[1] Houston Methodist Hosp, Div Infect Dis, Houston, TX USA
[2] Temple Univ, Dept Pharm Practice, Philadelphia, PA USA
[3] Houston Methodist Hosp, Infect Dis Fellowship & Educ, 6560 Fannin St, Ste 1512, Houston, TX 77030 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2023年 / 329卷 / 04期
关键词
D O I
10.1001/jama.2022.23954
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:291 / 292
页数:2
相关论文
共 50 条
  • [21] Fluvoxamine for outpatients with COVID-19: where do we stand?
    Berwanger, Otavio
    LANCET GLOBAL HEALTH, 2022, 10 (01): : E2 - E3
  • [22] Lack of efficacy of hydroxychloroquine in covid-19
    Vinetz, Joseph M.
    BMJ-BRITISH MEDICAL JOURNAL, 2020, 369
  • [23] Therapeutic potential of fluvoxamine in COVID-19 outpatients: a case report
    Rudez, Lorena Karla
    Sklebar, Tin
    Calusic, Martina
    Jurkovic, Ivan
    Kirsch, Steven
    Likic, Robert
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (12) : 4880 - 4881
  • [24] Fluvoxamine for non-hospitalized patients affected with COVID-19
    Wu, Peter E.
    Austin, Emily
    Leong, Derek
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (11) : E437 - E438
  • [25] COVID-19 benefit from statins?
    Devi, Sharmila
    LANCET INFECTIOUS DISEASES, 2021, 21 (04) : 467 - 467
  • [26] Elections and COVID-19 benefit payments
    Bessho, S.
    JOURNAL OF ASIAN ECONOMICS, 2023, 87
  • [27] Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19
    Mahdi, Mohamed
    Herman, Levente
    Rethelyi, Janos M.
    Balint, Balint Laszlo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)
  • [28] Why we should not recommend or offer fluvoxamine to COVID-19 patients?
    Trkulja, Vladimir
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (02) : 321 - 322
  • [29] Why we should not recommend or offer fluvoxamine to COVID-19 patients?
    Vladimir Trkulja
    European Journal of Clinical Pharmacology, 2023, 79 : 321 - 322
  • [30] Heme oxygenase agonists—fluvoxamine, melatonin—are efficacious therapy for Covid-19
    Philip L. Hooper
    Cell Stress and Chaperones, 2022, 27 : 3 - 4